Burns - Pipeline Review, H2 2016

Burns - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Burns - Pipeline Review, H2 2016’, provides an overview of the Burns pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Burns
    • The report reviews pipeline therapeutics for Burns by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Burns therapeutics and enlists all their major and minor projects
    • The report assesses Burns therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Burns
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Burns
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Burns Overview
    Therapeutics Development
    Pipeline Products for Burns - Overview
    Pipeline Products for Burns - Comparative Analysis
    Burns - Therapeutics under Development by Companies
    Burns - Therapeutics under Investigation by Universities/Institutes
    Burns - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Burns - Products under Development by Companies
    Burns - Products under Investigation by Universities/Institutes
    Burns - Companies Involved in Therapeutics Development
    Adocia
    AlgiPharma AS
    Amarantus Bioscience Holdings, Inc.
    American Gene Technologies International Inc.
    Biogenomics Limited
    CytoTools AG
    Destiny Pharma Limited
    Lakewood-Amedex Inc
    Madam Therapeutics B.V.
    MediWound Ltd.
    Mitochon Pharmaceuticals, Inc.
    Phosphagenics Limited
    Se-cure Pharmaceuticals Ltd.
    Sinclair Pharma Plc
    Stratatech Corporation
    Tissue Therapies Limited
    USV Pvt Ltd
    Burns - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    A-3APO - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AG-110 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    albumin (recombinant) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ALLO-ASC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biochaperone PDGF-BB - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bromelains - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Dermatology and Immunology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epidermal growth factor biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Burns - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMSP-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lidocaine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody Conjugate to Target TNF-alpha for Burns, Inflammation and Wounds - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MP-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Neu-2000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Nu-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligomer G for Wounds And Burns - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    P-12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    P-148 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PEP-04 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SC-106 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    silver sulfadiazine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Burn - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sodium hypochlorite - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VF-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XF-70 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Burns - Dormant Projects
    Burns - Discontinued Products
    Burns - Product Development Milestones
    Featured News & Press Releases
    Jun 07, 2016: MediWound’s NexoBrid Receives Reimbursement in Italy
    May 19, 2016: MediWound’s NexoBrid Highlighted in “Best Oral Presentation” at the British Burn Association 49th Annual Conference and Scientific Meeting
    May 02, 2016: MediWound’s NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting
    Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized
    Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
    Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters
    Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania
    Oct 20, 2015: Argentina's Ministry of Health Approves MediWound's NexoBrid
    Sep 30, 2015: MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S.
    Sep 29, 2015: MediWound Reports Highlights From the European Burns Association Congress
    Sep 10, 2015: MediWound's NexoBrid Highlighted at the 16th European Burns Association Congress
    Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting
    Apr 21, 2015: MediWound's NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting
    Apr 20, 2015: MediWound Initiates U.S. Phase 3 Trial With NexoBrid to Treat Severe Burns
    Mar 23, 2015: MediWound's NexoBrid Highlighted in a Presentation at the International Conference on Minimally Invasive Medicine
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Burns, H2 2016
    Number of Products under Development for Burns - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Investigation by Universities/Institutes, H2 2016
    Burns - Pipeline by Adocia, H2 2016
    Burns - Pipeline by AlgiPharma AS, H2 2016
    Burns - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
    Burns - Pipeline by American Gene Technologies International Inc., H2 2016
    Burns - Pipeline by Biogenomics Limited, H2 2016
    Burns - Pipeline by CytoTools AG, H2 2016
    Burns - Pipeline by Destiny Pharma Limited, H2 2016
    Burns - Pipeline by Lakewood-Amedex Inc, H2 2016
    Burns - Pipeline by Madam Therapeutics B.V., H2 2016
    Burns - Pipeline by MediWound Ltd., H2 2016
    Burns - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
    Burns - Pipeline by Phosphagenics Limited, H2 2016
    Burns - Pipeline by Se-cure Pharmaceuticals Ltd., H2 2016
    Burns - Pipeline by Sinclair Pharma Plc, H2 2016
    Burns - Pipeline by Stratatech Corporation, H2 2016
    Burns - Pipeline by Tissue Therapies Limited, H2 2016
    Burns - Pipeline by USV Pvt Ltd, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Burns - Dormant Projects, H2 2016
    Burns - Dormant Projects (Contd..1), H2 2016
    Burns - Dormant Projects (Contd..2), H2 2016
    Burns - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Burns, H2 2016
    Number of Products under Development for Burns - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook